A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury

Thrombosis and Haemostasis

Volumn 96, Issue 6, 2006, Pages 802-806

  Frank, Rolf Dario ^a,b   Holscher, Todd ^a   Schabbauer, Gernot ^a   Tencati, Michael ^a   Pawlinski, Rafal ^a   Weitz, Jeffrey I ^c   Mackman, Nigel ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Animal model; Anticoagulant; Inflammation; Ischemia reperfusion injury

Indexed keywords

ANTITHROMBIN; FONDAPARINUX; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; PADGEM PROTEIN; PENTASACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STRAIN U937; CHEMICAL MODIFICATION; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; KIDNEY ISCHEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY; STRUCTURE ANALYSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; BLOOD COAGULATION; CELL ADHESION; CHEMOKINE CCL2; CHEMOKINES; CREATININE; DISEASE MODELS, ANIMAL; FACTOR XA; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY; KIDNEY TUBULES; MACROPHAGES; MICE; NEUTROPHIL INFILTRATION; OLIGOSACCHARIDES; P-SELECTIN; PARTIAL THROMBOPLASTIN TIME; POLYSACCHARIDES; REPERFUSION INJURY; U937 CELLS;

EID: 33845358388     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-07-0418     Document Type: Article

References (18)

1. Weitz JI. New anticoagulants for treatment of venous thromboembolism. Circulation 2004; 110 (9 Suppl 1): 119-126.
2. Turpie AG, Eriksson BI, Lassen MR, et al. Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol 2003; 10: 327-32.
3. Herbert JM, HeraultJP, Bernat A, eta]. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-205.
4. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
5. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005; 11: 7003-11.
6. Ludwig RJ, Alban S, Bistrian R, et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 2006; 95: 535-40.
7. Tyrrell DJ, Horne AP, Holme KR, et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46: 151-208.
8. Wang L, Brown JR, Varki A, et al. Heparin's anti-inflammatory effects require glucosamine 6-0-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110: 127-36.
9. Koenig A, Norgard-Sumnicht K, Linhardt R, et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877-89.
10. Nelson RM, Cecconi O, Roberts WG, et al. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993 82: 3253-8.
11. Frank RD, Schabbauer G, Holscher T, et al. The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injury. J Thromb Haemost 2005; 3: 531-40.
12. Miura M, Fu X, Zhang QW, et al. Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. Am J Pathol 2001; 159: 2137-45.
13. Weitz JI, Young E, Johnston M, et al. Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation 1999; 99: 682-9.
14. Singbartl K, Green SA, Ley K. Blocking P-selectin protects from ischemia/ reperfusion-induced acute renal failure. FASEB J 2000; 14: 48-54.
15. Wei M, Tai G, Gao Y, et al. Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions. J Biol Chem 2004; 279: 29202-10.
16. Gao Y, Li N, Fei R, et al. P-Selectin-mediated acute inflammation can be blocked by chemically modified heparin, RO-heparin. Mol Cells 2005; 19: 350-5.
17. Wei M, Gao Y, Tian M, et al. Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells. Cancer Lett 2005; 229: 123-6.
18. Gao Y, Wei M, Zheng S, et al. Chemically modified heparin inhibits the in vitro adhesion of nonsmall cell lung cancer cells to P-selectin. J Cancer Res Clin Oncol 2006; 132: 257-64.